Cargando…

Differential expression of VEGFR2 protein in HER2 positive primary human breast cancer: potential relevance to anti-angiogenic therapies

BACKGROUND: Clinically relevant predictive biomarkers to tailor anti-angiogenic therapies to breast cancer (BRC) patient subpopulations are an unmet need. METHODS: We analyzed tumor vascular density and VEGFR2 protein expression in various subsets of primary human BRCs (186 females; Mean age: 59 yea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nasir, Aejaz, Holzer, Timothy R., Chen, Mia, Man, Michael Z., Schade, Andrew E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Primary Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5438568/ https://www.ncbi.nlm.nih.gov/pubmed/28533703 http://dx.doi.org/10.1186/s12935-017-0427-5

Ejemplares similares

Acidic pH reduces VEGF-mediated endothelial cell responses by downregulation of VEGFR-2; relevance for anti-angiogenic therapies
por: Faes, Seraina, et al.
Publicado: (2016)

VEGFR2 heterogeneity and response to anti-angiogenic low dose metronomic cyclophosphamide treatment
por: Patten, Steven G, et al.
Publicado: (2010)

Development of a risk scoring system for evaluating the prognosis of patients with Her2-positive breast cancer
por: Gao, Chundi, et al.
Publicado: (2020)

Genetic variants of VEGFR-1 gene promoter in acute myocardial infarction
por: Wang, Haihua, et al.
Publicado: (2019)

The in vitro influences of epidermal growth factor and heregulin-β1 on the efficacy of trastuzumab used in Her-2 positive breast adenocarcinoma
por: Hurrell, Tracey, et al.
Publicado: (2013)

Discovery and evaluation of triple inhibitors of VEGFR-2, TIE-2 and EphB4 as anti-angiogenic and anti-cancer agents
por: Zhang, Lin, et al.
Publicado: (2017)

The development and initial validation of the Health and Reproductive Survey (HeRS)
por: Duffy, Donna, et al.
Publicado: (2021)

Novel Anti-Angiogenic and Anti-Tumour Activities of the N-Terminal Domain of NOEY2 via Binding to VEGFR-2 in Ovarian Cancer
por: Rho, Seung Bae, et al.
Publicado: (2021)

Growth of MCF-7 breast cancer cells and efficacy of anti-angiogenic agents in a hydroxyethyl chitosan/glycidyl methacrylate hydrogel
por: Wang, Hejing, et al.
Publicado: (2017)

Anti-angiogenic effects of differentiation-inducing factor-1 involving VEGFR-2 expression inhibition independent of the Wnt/β-catenin signaling pathway
por: Yoshihara, Tatsuya, et al.
Publicado: (2010)

Lipoplex-based targeted gene therapy for the suppression of tumours with VEGFR expression by producing anti-angiogenic molecules
por: Ho, Shu-Yi, et al.
Publicado: (2020)

Efficacy and challenges of a culturally relevant intervention to improve attitudes to aging
por: Seah, Siang Joo, et al.
Publicado: (2019)

Aptamer-modified magnetic nanoprobe for molecular MR imaging of VEGFR2 on angiogenic vasculature
por: Kim, Bongjune, et al.
Publicado: (2013)

Endothelial Ca(2+) oscillations reflect VEGFR signaling-regulated angiogenic capacity in vivo
por: Yokota, Yasuhiro, et al.
Publicado: (2015)

Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level
por: Atallah, N. M., et al.
Publicado: (2023)

Notch regulates the angiogenic response via induction of VEGFR-1
por: Funahashi, Yasuhiro, et al.
Publicado: (2010)

ZLM-7 exhibits anti-angiogenic effects via impaired endothelial cell function and blockade of VEGF/VEGFR-2 signaling
por: Su, Min, et al.
Publicado: (2016)

Establishment and characterization of three stable Basal/HER2-positive breast cancer cell lines derived from Chinese breast carcinoma with identical missense mutations in the DNA-binding domain of TP53
por: Zhou, Fei, et al.
Publicado: (2018)

Single nucleotide polymorphisms in the angiogenic and lymphangiogenic pathways are associated with lymphedema caused by Wuchereria bancrofti
por: Debrah, Linda Batsa, et al.
Publicado: (2017)

CD4 T-cell immune stimulation of HER2 + breast cancer cells alters response to trastuzumab in vitro
por: Song, Patrick N., et al.
Publicado: (2020)

Apatinib preferentially inhibits PC9 gefitinib-resistant cancer cells by inducing cell cycle arrest and inhibiting VEGFR signaling pathway
por: Song, Yong-An, et al.
Publicado: (2019)

VEGFR2 promotes tumorigenesis and metastasis in a pro-angiogenic-independent way in gastric cancer
por: Lian, Lian, et al.
Publicado: (2019)

Suppressing VEGF-A/VEGFR-2 Signaling Contributes to the Anti-Angiogenic Effects of PPE8, a Novel Naphthoquinone-Based Compound
por: Hsu, Ming-Jen, et al.
Publicado: (2022)

Correlation between HER-2/neu(erbB-2) expression level and therapeutic effect of combination treatment with HERCEPTIN and chemotherapeutic agents in gastric cancer cell lines
por: Cui, Hai, et al.
Publicado: (2014)

The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial
por: Pizzuti, Laura, et al.
Publicado: (2021)

Celecoxib alleviates tamoxifen-instigated angiogenic effects by ROS-dependent VEGF/VEGFR2 autocrine signaling
por: Kumar, B N Prashanth, et al.
Publicado: (2013)

SALM4 regulates angiogenic functions in endothelial cells through VEGFR2 phosphorylation at Tyr1175
por: Kim, Dong Young, et al.
Publicado: (2019)

Unraveling the Angiogenic Puzzle: Pre-Treatment sVEGFR1 and sVEGFR2 Levels as Promising Prognostic Indicators in Early-Stage Breast Cancer Patients
por: Zarychta, Elżbieta, et al.
Publicado: (2023)

Sphingosine-1-Phosphate Receptor 1 Activity Promotes Tumor Growth by Amplifying VEGF-VEGFR2 Angiogenic Signaling
por: Ragunathrao, Vijay Avin Balaji, et al.
Publicado: (2019)

Anti-HER2 Drugs for the Treatment of Advanced HER2 Positive Breast Cancer
por: Stanowicka-Grada, Malwina, et al.
Publicado: (2023)

Salinomycin exhibits anti-angiogenic activity against human glioma in vitro and in vivo by suppressing the VEGF-VEGFR2-AKT/FAK signaling axis
por: Bi, Yan-Ling, et al.
Publicado: (2017)

Exosomes from cervical cancer cells facilitate pro-angiogenic endothelial reconditioning through transfer of Hedgehog–GLI signaling components
por: Bhat, Anjali, et al.
Publicado: (2021)

A Computational Approach to Modeling an Antagonistic Angiogenic VEGFR1-IL2 Fusion Protein for Cancer Therapy
por: Shafique, Qurrat ul Ain, et al.
Publicado: (2021)

Synergistic Anti-Angiogenic Effect of Combined VEGFR Kinase Inhibitors, Lenvatinib, and Regorafenib: A Therapeutic Potential for Breast Cancer
por: Bajbouj, Khuloud, et al.
Publicado: (2022)

Comprehensive Analysis of VEGFR2 Expression in HPV-Positive and -Negative OPSCC Reveals Differing VEGFR2 Expression Patterns
por: Uzun, Senem, et al.
Publicado: (2021)

Analysis of ACE2 genetic variants in 131 Italian SARS-CoV-2-positive patients
por: Novelli, Antonio, et al.
Publicado: (2020)

Clinical relevance of thyroid cell models in redox research
por: Cammarota, Francesca, et al.
Publicado: (2015)

Old Player-New Tricks: Non Angiogenic Effects of the VEGF/VEGFR Pathway in Cancer
por: Ntellas, Panagiotis, et al.
Publicado: (2020)

Establishment and characterization of two human breast carcinoma cell lines by spontaneous immortalization: Discordance between Estrogen, Progesterone and HER2/neu receptors of breast carcinoma tissues with derived cell lines
por: Kamalidehghan, Behnam, et al.
Publicado: (2012)

Ponatinib exerts anti-angiogenic effects in the zebrafish and human umbilical vein endothelial cells via blocking VEGFR signaling pathway
por: Ai, Nana, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ptgo9r99hhi27t7biqtfe674ps